Aeterna Zentaris Inc. (NASDAQ:AEZS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

Other research analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Aeterna Zentaris in a research report on Sunday, July 10th. Maxim Group reissued a “buy” rating and issued a $11.00 price target on shares of Aeterna Zentaris in a research report on Saturday, August 13th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $9.00 price target on shares of Aeterna Zentaris in a research report on Tuesday, August 23rd.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Aeterna Zentaris (NASDAQ:AEZS) traded up 3.29% on Tuesday, reaching $3.45. The company’s stock had a trading volume of 161,660 shares. Aeterna Zentaris has a 1-year low of $2.60 and a 1-year high of $15.70. The firm’s 50 day moving average price is $3.51 and its 200-day moving average price is $3.54. The company’s market capitalization is $34.29 million.

Aeterna Zentaris (NASDAQ:AEZS) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.82) by $0.11. Aeterna Zentaris had a negative return on equity of 241.78% and a negative net margin of 5,871.45%. Equities analysts forecast that Aeterna Zentaris will post ($2.61) earnings per share for the current year.

An institutional investor recently raised its position in Aeterna Zentaris stock. Renaissance Technologies LLC raised its stake in Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned about 8.17% of Aeterna Zentaris worth $1,716,000 as of its most recent filing with the SEC. 8.28% of the stock is currently owned by institutional investors.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

5 Day Chart for NASDAQ:AEZS

Get a free copy of the Zacks research report on Aeterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related companies with's FREE daily email newsletter.